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Introduction: We have evaluated the use of silica–dopamine reservoirs synthesized by the 
  sol–gel approach with the aim of using them in the treatment of Parkinson’s disease, specifically 
as a device for the controlled release of dopamine in the striatum. Theoretical calculations 
illustrate that dopamine is expected to assume a planar structure and exhibit weak interactions 
with the silica surface.
Methods: Several samples were prepared by varying the wt% of dopamine added during the 
hydrolysis of tetraethyl orthosilicate. The silica–dopamine reservoirs were characterized by 
N2 adsorption, scanning and transmission electron microscopy, and Fourier transform infrared 
spectroscopy. The in vitro release profiles were determined using ultraviolet visible absorbance 
spectroscopy. The textural analyses showed a maximum value for the surface area of 620 m2/g 
nanostructured silica materials. The stability of dopamine in the silica network was confirmed 
by infrared and 13C-nuclear magnetic resonance spectroscopy. The reservoirs were evaluated 
by means of apomorphine-induced rotation behavior in hemiparkisonian rats.
Results: The in vitro dopamine delivery profiles indicate two regimes of release, a fast and 
sustained dopamine delivery was observed up to 24 hours, and after this time the rate of deliv-
ery became constant. Histologic analysis of formalin-fixed brains performed 24–32 weeks 
after reservoir implantation revealed that silica–dopamine implants had a reddish-brown color, 
suggesting the presence of oxidized dopamine, likely caused by the fixation procedure, while 
implants without dopamine were always translucent.
Conclusion: The major finding of the study was that intrastriatal silica–dopamine implants 
reversed the rotational asymmetry induced by apomorphine, a dopamine agonist, in 
hemiparkinsonian rats. No dyskinesias or other motor abnormalities were observed in animals 
implanted with silica or silica–dopamine.
Keywords: Parkinson’s disease, silica–dopamine, controlled drug release, central nervous 
system, reservoirs
Introduction
Parkinson’s disease is an illness of the central nervous system that leads to severe 
impairment of motor skills and difficulty in controlling body movements. The 
characteristic symptoms are tremor, rigidity, slowed body movements (bradykinesia), 
unstable posture, and difficulty in walking.1–3 Smoking, alcohol, coffee, cocaine, amphet-
amine, and opiate abuse have all been shown to have somewhat of a preventative effect 
in the onset of Parkinson’s disease.4–6 Parkinson’s disease is characterized by a progres-
sive degeneration of dopaminergic neurons in the substantia nigra pars compacta region 
of the brain, leading to a massive loss of dopamine in the striatum.7 To date, Parkinson’s International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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disease remains an incurable disease. Because dopamine does 
not cross the blood–brain barrier, it cannot be used as replace-
ment therapy in patients with Parkinson’s disease.8 Instead, 
its immediate precursor, L-  hydroxyphenylalanine (L-dopa), 
has good brain   penetration, rendering it the most efficacious 
treatment. However, during long-term use of L-dopa, many 
patients with Parkinson’s disease develop motor response 
fluctuations that, in many cases, force treatment discontinu-
ation (eg, wearing off, on-off fluctuations, night-time deterio-
ration, early morning worsening, and dyskinesias).9,10 These 
side effects have been linked to fluctuations of striatal dop-
amine levels during intermittent L-dopa therapy, and some 
success in reducing them has been obtained with the use of 
slow-release L-dopa formulations.11 The currently available 
pharmacologic and nonpharmacologic treatments are capable 
of offering only symptomatic relief for patients.12
One way to combat this problem is to develop con-
trolled drug-release systems for reducing drug dosage and 
to make the drug available at the target sites. A large variety 
of such systems have been developed and used, including 
liposomes, micelles, dendrimers, and copolymers.13 Oxide 
nanomaterials have recently attracted attention as potential 
drug-release carriers due to their versatile physiochemical 
properties, including easy synthesis, tailorable surface charge 
density and facile surface functionalization, good biocom-
patibility, and low cytoxicity.14–16 In particular, silica-based 
materials have attracted interest17–20 due to their excellent 
biocompatibility and because they can be engineered into a 
variety of nanoshapes. Furthermore, the rate of bioerosion 
can be tuned by changes in the synthesis or postprocessing 
conditions.21 Therefore, sol–gel-derived silica xerogels have 
been studied as carrier materials for the controlled release of 
various drugs, proteins, and peptides.22–24 Using this mate-
rial, we previously showed an antiepileptic effect in rats 
implanted with a valproic acid-loaded nanosilica reservoir 
in the amygdala.25 Recently, we described the stabilization 
of dopamine in a nanosilica sol–gel matrix to be used as a 
controlled drug-release system.26
In this work, dopamine was incorporated into a silica 
network structure using the sol–gel method. The reservoirs 
were characterized by a variety of methods in order to evalu-
ate the stability of the dopamine molecule in the nanomate-
rial, as well as the interactions between the drug and the silica 
network. The aim of this work was to obtain a drug-release 
device for use as an intracranial implant, specifically in dam-
aged regions. For this purpose, we evaluated the therapeutic 
efficacy of striatal dopamine release from a silica reservoir 
in hemiparkinsonian rats by studying the circling behavior 
induced by apomorphine before and after the implantation, in 
a similar fashion to the experimental design used in studies 
of cell transplants.27
Methods
Theoretical analysis
Calculations were performed using local density approxima-
tion. Density functional theory was employed using DMo13 
high precision software. The models were established 
and then geometrically optimized. This was followed by 
a calculation of the single point-to-point energy in order 
to identify the most stable energy state, the electrostatic 
potential associated with the molecule, and the characteristic 
Fukui potentials, as previously reported.28
Preparation of silica–dopamine
Four different samples of silica, containing 9.09, 19.2, 33.33 
and 42.85 wt% of dopamine, were prepared by the sol–gel 
process. In general terms, the following procedure was car-
ried out for each sample: 2, 5, 10, and 15 g of dopamine (99%; 
Sigma-Aldrich, St. Louis, MO) were dissolved in 239 mL 
of water. Afterwards, 68.74 g of tetraethoxysilane (Sigma-
Aldrich) were added dropwise to this solution. The resulting 
solution was continuously stirred at room temperature until 
gel formation, and the obtained gel was dried at 80°C. The 
drying process was carried out in nitrogen atmosphere in 
order to avoid the oxidation of dopamine.
characterization
13c-nuclear magnetic resonance spectroscopy
The spectra were obtained using a Varian Gemoni 200 spec-
trometer (Varian, Palo Alto, CA).
Fourier transform infrared spectroscopy
Silica–dopamine samples were mixed with KBr (5 wt%) and 
pressed into transparent wafers. Fourier transform infrared 
spectra were recorded using a Perkin-Elmer 1600 spectropho-
tometer (Perkin-Elmer, Shelton, CT) in the 4000–400 cm−1 
range, and 32 scans were run for each measurement.
Textural properties
Adsorption-desorption measurements were performed on 
an ASAP 2010 Micromeritic apparatus (Micrometrics, 
Atlanta, GA). The samples were previously degassed at room 
temperature and 10−3 Torr for several hours. Adsorption-
desorption measurements were then performed at liquid 
nitrogen temperature (77 K) and 10−6 Torr vacuum pressure. 
Successive known volumes of N2 gas were admitted to the International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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adsorbent at programmed intervals and equilibrium pressure 
was measured. Similarly, desorption isotherms were obtained 
by measuring the quantities of gas removed from the sample 
as the relative pressure was lowered. Analysis of the surface 
area of the samples was done according to the most widely 
used procedure of the Brunauer–Emmett–Teller (BET) 
method. Pore size distributions and adsorbed volume were 
calculated using the Barrett, Joyner, and Halenda (BJH) 
theory and desorption branches, respectively.
Transmission electron microscopy
Particle size was measured using conventional transmission 
electron microscopy (TEM, Zeiss EM910; Carl Zeiss, 
Oberkochen, Germany), operated at 100 kV , with a side entry 
goniometer and 0.4 nm point-to-point resolution, and attached 
to a CCD camera (MegaVision, Santa Barbara, CA).
In vitro dopamine release
Dopamine release measurements were carried out by 
means of ultraviolet-visible spectrophotometry utilizing a 
Varian CARY 1 instrument (Varian). The absorbance was 
monitored at λ = 280 nm. In order to avoid dopamine oxi-
dation, it was necessary to use a nitrogen atmosphere and 
an amber recipient, as shown in Figure 1. Each sample was 
compressed into a tablet of 19.8, 12.7, 18.4, and 8.3 mg 
for each sample in increasing order of dopamine content 
and immersed in 200 mL of deionized water. At predeter-
mined time intervals, 4 mL of the solution was withdrawn, 
and the ultraviolet-visible absorbance spectrum was mea-
sured. After each measurement, the aliquot was returned 
to the original solution. A calibration curve of absorbance 
versus dopamine concentration was used to determine 
the concentration of released dopamine, as shown in   
Figure 2.
In vivo dopamine studies
Experiments were conducted on 17 male Wistar rats bred 
in our facilities. The initial average weight was 229 ± 9 g 
(range 238–268 g), which increased to 415 ± 10 g (range 
345–495 g) at the end of the experimental period. Animals 
were individually housed in acrylic cages at constant room 
temperature (23 ± 1°C) and maintained on a 12:12 hour light/
dark cycle (lights on at 7am) throughout. Food and water 
were available ad libitum. All efforts were made to mini-
mize animal discomfort according to the recommendations 
of the Guide for the Care and Use of Laboratory Animals 
(National Research Council of USA, 1996). This study was 
approved by the Institutional Bioethics Committee of the 
CIR-UADY.
Following an intraperitoneal dose of desipramine 
25 mg/kg to protect the central noradrenergic neurons, rats 
were anesthetized with intraperitoneal sodium pentobarbital 
45 mg/kg and placed in a stereotaxic frame (Stöelting, 
Wood Dale, IL) with the incisor bar set at 3.3 mm below 
the interaural line. A single dose of 6-hydroxydopamine 
9 µg/3 µL, (Sigma-Aldrich) was manually injected in small 
Figure 1 set-up for the study of dopamine release from silica reservoirs. The 
experiments were performed in amber glass bottles and under nitrogen atmosphere 
in order to prevent dopamine oxidation.
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Figure 2 Absorbance spectra of standard solutions as a function of dopamine 
concentration.  The  inset  shows  the  calibration  curve  used  to  determine  the 
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steps (at approximately 0.2 µL/min) into the right substantia 
nigra pars compacta, at the coordinates AP, −5.3 mm from 
bregma; L, −1.8 mm from the midline, and V, −7.6 mm from 
the dura surface.29 Infusion was made through a 30 gauge 
needle connected with a polyethylene catheter (PE10) to a 
10 µL microsyringe (Hamilton, Reno, NV). Upon completion 
of the injection, the needle was left in place for an additional 
minute before withdrawal.
In order to select those animals bearing successful 
striatal dopamine denervation (.90%) they were tested 
for apomorphine-induced rotation two weeks after lesion 
surgery. The rotational test was done by placing the rats in 
hemispheric bowls (41 cm diameter), secured to a harness, 
and connected with a steel wire to an automated rotometer.30 
A subcutaneous dose of apomorphine 0.25 mg/kg was 
then applied, and the rotational behavior counted during 
90 minutes. Only rats performing a minimum of 100 
complete turns (360o) contralateral to the lesioned side 
during the 90-minute test were used in the experiments 
(Figure 3).
The selected rats were divided in three groups: rats with-
out implant surgery (lesion-only group), rats implanted with 
empty silica reservoirs (silica group), and rats implanted with 
reservoirs impregnated with dopamine (silica–dopamine 
group). The second rotational test was performed in the 
same way 24 weeks after the lesion, which corresponded to 
16 weeks after surgical implantation of the nanostructured 
reservoirs in the striatum (Figure 3). This last test allowed 
assessment of whether the rats with silica–dopamine 
implants experienced the expected reduced behavioral 
asymmetry in comparison with lesion-only animals or those 
implanted with the empty silica reservoir. The reduction or 
increase in the number of contralateral turns (CLT) between   
the first (two weeks) and the second (24 weeks) rotational 
tests after the 6-hydroxydopamine lesion was measured as 
the percent change (∆CLT%), according to the formula:
∆CLT% =   (CLT  24  weeks  –  CLT  2  weeks)/
(CLT 2 weeks) × 100.
surgical implantation
Surgical implantation of silica reservoirs was done during 
the eighth week after the 6-hydroxydopamine lesion. Rats 
were anesthetized and placed in a stereotaxic frame as before. 
About 1.5 mg of the nanosilicon powder, either silica or 
silica–dopamine, was packed into the lumen of a 17 gauge 
stainless steel unbeveled rachidian needle. The resulting 
cylinders were approximately 1 mm in diameter and 2 mm 
in length. One silica cylinder with or without dopamine was 
surgically implanted into the right striatum by gently pushing 
the nanosilica material with a steel piston, such that the lower 
end of the implanted cylinder would be positioned at the 
following coordinates: AP, 1.0 mm from bregma; L, −3.3 mm 
from the midline, and V, −6.5 mm from the dura surface.31 
After recovering from the surgery, rats remained in their home 
cages with food and water ad libitum for one month before 
starting the behavioral tests.
histology
Once the behavioral tests had been completed, rats were 
anesthetized and perfused through the ascending aorta with 
phosphate-buffered saline (0.1 M, pH 7.4) followed by ice-
cold paraformaldehyde 4% in phosphate-buffered saline. This 
occurred between 16 and 28 weeks after surgical implantation 
of the silica. The brains were removed, postfixed for two 
hours in the same fixative at room temperature, and placed 
overnight in phosphate-buffered saline with 15% sucrose at 
4oC. Serial coronal sections (50 µm) of the striatum were 
cut using a vibroslicer (Vibratome, Bannockburn, IL) and 
sequentially placed in multiwells with phosphate-buffered 
saline. Freshly cut sections of striatum at the level of the 
implants (silica or silica–dopamine) were photographed with 
a digital camera (Olympus DP11) adapted to a stereoscopic 
microscope Olympus SZ11 (Olympus, Tokyo, Japan).
Data analysis
In compliance with international policies for the use of ani-
mals in neuroscience research, the number of rats used in this 
study was kept to the minimum necessary to obtain statisti-
cally significant results. Data are expressed as means ± stan-
dard error of the mean. The time-courses of circling behavior 
during weeks 2 and 24 were analyzed using two-way analysis 
of variance, and the cumulative rotation values were com-
Weeks
0
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24
LESION
Sequence of testing
Circling behavior test
IMPLANTATION
Circling behavior test
Histology
Figure 3 experimental design. In all experimental groups, the circling behavior tests 
were performed two and 24 weeks after the unilateral nigral 6-hydroxydopamine 
lesion. In two groups of lesioned rats, a silica nanostructured material, with or 
without dopamine, was surgically implanted in the dopamine denervated striatum 
during the eighth week after the lesion.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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pared using the paired Student’s t-test. The percent change 
between the first and second rotation tests did not follow a 
normal distribution, and hence data were analyzed using the 
Kruskal–Wallis test, followed by Dunn’s post hoc multiple 
comparison test. The significance level was set at 0.05. All 
statistical analyses were performed using GraphPad Prism 
version 4 (GraphPad Software Inc, La Jolla, CA).
Results and discussion
In Figure 4, the structural analysis of a dopamine molecule 
is represented. Possible modifications in its electronic struc-
ture as a result of the presence of H atoms can be observed 
following the approach of a nanostructured silica unit. This 
was used to identify the electrophilic and nucleophilic sites. 
As a result of these calculations (Figure 4) it is possible to 
understand that the most stable configuration tends to place 
the ring of the molecule in a planar structure, enabling 
equivalent interactions with any of its atoms as a function of 
structure and electron affinity. It is precisely this electrostatic 
potential that shows how the sites in close proximity to the 
nitrogen atoms and those that surround the benzene ring in 
the direction of the oxygen atoms clearly define the polarity 
of the molecule.31,32
The isosurface of the highest occupied molecular orbital 
of the molecule is centered on the ring, leaving only a small 
residue outside. This phenomenon modifies the application 
of dopamine, because the associated chemical potential is 
totally different. The evident effects on the silica–dopamine 
system can be seen in the location of the electrophilic sites 
[f(−)] and nucleophilic sites [f(+)] that define the tendency 
for reactions. Figure 5 shows the location of the sites for 
two conditions, a) when the dopamine is considered as a 
neutral molecule, and b) in the presence of hydrogen atoms, 
whereby the distribution of the sites is strongly modified in 
the presence of hydrogen. It is clear that the modified system 
should be more reactive and thus becomes the preferred 
reaction pathway in interactions with the silica reservoir. 
This behavior causes the functional groups of dopamine 
(NH and OH) to interact efficiently with the receptors of the 
sol–gel silica matrix.
In order to evaluate the interaction modes in the molecule 
without previous perturbation, a geometric optimization cal-
culation of one dopamine molecule in the proximity of a nano-
structured silica segment was performed. The most feasible 
interactions stabilized the dopamine in the hydroxylated 
sol–gel silica. This process is illustrated in Figure 6. The 
calculations were performed using two different orientations 
for the initial step: a dopamine molecule above the nanostruc-
tured silica reservoir (Figure 6a), and a dopamine molecule 
besides the nanostructured silica reservoir (Figure 6b). It was 
found that dopamine is attracted to the silica in a coplanar 
form. Nevertheless, the minimum energy was obtained when 
the molecule was linked to the silica network via the silanol 
groups and the amine, carboxyl, and hydroxyl groups of the 
drug, which are characterized by noncovalent and weak interac-
tions. Hence, dopamine molecules were completely stable in 
the silica nanomaterial26 (a white material was obtained), and 
this is in agreement with the 13C-nuclear magnetic resonance 
spectroscopy analysis, which indicated that drug degradation 
was not observed, as shown in Figure 7. Likewise, the two 
coordination types between the drug and silica also show 
H
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HOMO LUMO
Electrostatic
potential
Figure  4  Atomic  and  electron  structure  of  dopamine  calculated  by  quantum 
mechanical methods, also illustrating the highest occupied molecular orbital and 
lowest unoccupied molecular orbital spatial distribution.
f(−) f(+)
f(−) f(+)
A
B
Figure  5  calculated  atomic  and  electron  structure  of  dopamine  A)  Neutral 
molecule and B) in the presence of hydrogen atoms (see text for details).International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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hydrogen bonds. The presence of OH groups generates a pas-
sive section in the inorganic matrix and a deformation of the 
network is observed (Figures 6c and 6d). The hydrogen bridges 
are somewhat stronger than the other interactions, although this 
does not impede release of the drug in an aqueous medium, 
such as cerebrospinal fluid. These results illustrate that the 
silica–dopamine system shows promising characteristics for 
brain drug-release systems.
Textural properties
The N2 adsorption-desorption isotherms of the four samples 
are shown in Figure 8. Approximately 80%–90% of the 
total uptake at 0.7 P/P0 takes place within 0.7–1.0 P/P0. The 
isotherms exhibit a steep slope and hysteresis at relative pres-
sures higher than 0.7, which may be associated with capillary 
condensation in larger mesopores, and the isotherms can be 
classified as Type IV according to International Union of 
Pure and Applied Chemistry definitions.33 The hysteresis loop 
observed for 9.09 wt% and 19.2 wt% samples indicates a 
textural mesoporosity in the particle aggregates, thus evidenc-
ing the presence of external surfaces between the particles. 
However, the hysteresis loop observed for the 33.33 wt% and 
42.85 wt% materials indicates the presence of spaces between 
parallel sheet structures. In all samples the N2 uptake at higher 
P/P0 values is due to the dominating presence of mesopores. 
The mesoporosity of silica obtained from the sol–gel process 
through hydrolysis of silicon alkoxide in the presence of an 
organic additive has been attributed to electrostatic interaction 
between the silica sol particles and the organic additive. We 
consider that the same mechanism prevails in the formation 
of mesoporous silica in the silica–dopamine system. The 
structure-directing effect of dopamine in the silica gel com-
plex is that of cooperative organization between the organic 
and inorganic groups. It may be noted here that the sol–gel 
process produces silica particles in the nanometer length 
range; however, when dopamine is added at high concentra-
tion, the nanomaterial structures constitute parallel sheets.
The pore sizes of the samples were obtained using the 
BJH theory,34 which takes into account the formation of a 
liquid-like adsorbate layer on the pore walls which precedes 
capillary condensation or follows capillary evaporation. 
In order to measure the thickness of the adsorbate layer, t, 
on the adsorbate relative pressure, x (x =P/P0, where P is 
the adsorbate pressure and P0 is the adsorbate vapor pressure 
at the measuring temperature), a ‘‘universal’’ dependence, 
t(x), is used, which is believed to apply for diverse surface 
types of porous solids. The pore size distribution using the 
desorption branch of N2 isotherms are shown in Figure 9. 
The 19.2 wt% sample presents a wide pore size distribution, 
while the rest of the samples present a narrow one.
The BET surface area, volume pore, and average pore 
size are summarized in Table 1. The BET surface areas 
were calculated from the BET plots at the P/P0 range of 
0–0.4. From these data, we can deduce that the sample 
with 19.22 wt% of dopamine has the largest surface area of 
620 m2/g. At either higher or lower dopamine concentrations, 
the surface area of the reservoir materials is approximately 
100 m2/g. In general, the average pore size is between 
100 and 200 Å for all samples, corresponding to mesopo-
rous materials. The corresponding mesopore volume for all 
samples is approximately 0.4 cc/g (see Table 1).
Fourier transform infrared spectroscopy
The Fourier transform infrared spectra of dopamine and 
silica–dopamine samples are shown in Figures 10 and 11, 
respectively. A wide band at low energy enclosing three 
important peaks is observed for dopamine, as shown in 
Figure 9. The peaks at 3350 cm−1, 3205 cm−1, and 3034 cm−1 
are assigned to stretching vibrations of the OH, CN, and 
NH groups of dopamine, respectively. Other small peaks 
are observed in the range of 2778–2170 cm−1, correspond-
ing to different CH vibrations of either aryl or aliphatic CH 
bonds. At higher energies, important bands are observed at 
1494 cm−1 and at 1252 cm−1, corresponding to the bending 
vibration of CH and the aryl oxygen stretching vibration, 
respectively. The peak at 1342 cm−1 is attributed to the OH 
groups of the dopamine molecule.
A
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Figure 6 calculated structure of a silica net segment and geometric optimization of 
the framework with one dopamine molecule: A) original configuration, B) relaxed 
structure, C) top view of the deformation of the silica framework with dopamine, 
and D) side view.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Figure 11 shows the spectra corresponding to dopamine 
loaded into the silica network, and it can be seen that the peaks 
corresponding to the OH, CN, and NH vibrations of dopamine 
become better defined and stronger with increasing dopamine 
concentrations. However, the peaks are shifted to slightly 
higher energies, which is attributed to weak interactions, 
such as Van der Waals forces and hydrogen bridges between 
dopamine and the hydroxyl groups of the silica matrix.26 The 
peaks corresponding to the bending vibration of CH groups 
and the stretching vibration of the aryl oxygen of dopamine 
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were also observed at somewhat higher energies. These results 
suggest that dopamine was successfully loaded in the silica 
sol–gel matrix and that the drug is stable.
The most important bands corresponding to silica 
structures were also observed in the spectrum shown in 
Figure 11. A band centered at 3385 cm−1 is attributed to 
the OH stretching vibrations of silanol groups. The band 
localized at 1632 cm−1 is related to adsorbed water and is 
generated by symmetric stretching vibrations of the hydro-
gen atoms with the oxygen atom. A high intensity band at 
1092 cm−1 accompanied by a shoulder at 1210 cm−1 are due 
to asymmetric stretching vibrations of ≡ Si-O-Si ≡. The band 
at 956 cm−1 is due to the silanol groups. Another band pres-
ent at 805 cm−1 is due to asymmetric flexion of the ≡Si-O 
bonds.35 Finally, the band at 566 cm−1 appears to be due to 
bending vibrations of O-Si-O.
Transmission electron microscopy
Figure 12 shows TEM images of the silica–dopamine 
materials with varying concentrations of dopamine. In gen-
eral terms, all samples show a morphology consisting of 
aggregated particles, with sizes depending on the dopamine 
concentration. For the sample with 9.09 wt% of dopamine, 
the particle size was found to be 50–150 nm. Most likely 
these particles consist of aggregated nanoparticles, thus 
accounting for the presence of mesopores with an average 
size of about 10 nm. For the sample of silica containing 
Table 1 BeTAreA, average pore diameter, and pore volume of 
different silica–dopamine materials
Sample BETAREA  
m2/g
Pore  
diameter (Å)
Pore  
volume (cc/g)
siO2-DA 9.09 100 170 0.4291
siO2-DA 19.2 620 147 2.2866
siO2-DA 33.33 172 101 0.4374
siO2-DA 42.85 136 124 0.4261
Abbreviations: BeTAreA, area calculated by the Brunauer–emmett–Teller 
method; siO2-DA, silica–dopamine.
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dopamine 19.2 wt%, the average particle size was around 
40 nm, while most of the particles in the sample with 33.33 
dopamine wt% had a size of approximately 25 nm. The 
sample with the highest content of dopamine at 42.85 wt% 
had a particle size of around 15 nm. These results indicate 
that the presence of dopamine during the preparation of the 
silica matrix strongly affects the morphology of the reservoir 
material. Interestingly, the dependence of the particle size on 
the dopamine concentration appears much more pronounced 
than that of the average size of pores.
X-ray diffraction
The X-ray diffraction patterns of silica–dopamine materials 
are shown in Figure 13, in which an undefined broad band 
characteristic of amorphous silica is shown. Diffraction peaks 
corresponding to dopamine were not seen, thus indicating 
that dopamine was highly dispersed into the amorphous 
network of silica.
In vitro dopamine release kinetics
The release kinetic profiles of dopamine from the silica–
dopamine reservoir materials were studied for 100 hours 
using ultraviolet visible spectrophotometry, and the results 
are shown in Figures 14 and 15. The kinetic profiles were 
obtained by quantifying the accumulated amount of dop-
amine released as a function of time, and are shown in 
Figure 14, and correspond to the 9.09 wt% silica–dopamine 
sample. From Figure 15 it can be observed that, in all cases, 
the silica–dopamine reservoirs show a sharp initial burst of 
dopamine release during the first 24 hours. This is attributed 
to the immediate dissolution and release of the portion 
of the drug located on and near the surface of the disks. 
The amount of released dopamine can be compared with 
the amount of incorporated dopamine. For the 9.09 wt% 
sample, 1.68 mg of dopamine were originally present in 
the reservoir, and essentially 70% of this was released at 
24 hours. This can be related to the morphology observed 
with TEM, which showed relatively large particle sizes, 
suggesting the presence of macropores. It appears that, in 
this case, the majority of the dopamine was incorporated 
in macropores, allowing fast release upon immersion in 
a solution. For the 19.2 wt% sample, about 2.45 mg of 
dopamine were incorporated, and about 20% was released 
within the first 24 hours. Further release of the remaining 
dopamine appears to be very slow, as evidenced by the 
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essentially time-independent dopamine concentration in the 
solution. For the sample with 33.33 wt% dopamine, about 
50% of it was released within the first 24 hours, whereas for 
the 42.85 wt% sample about 4.5% was released during the 
first 24 hours. Hence, it can be concluded that the release 
kinetics depend on the morphology and composition of 
the silica–dopamine reservoir material, the general trend 
being that initially less dopamine is released with smaller 
particle size, as observed with TEM. Also, the efficient 
initial release of dopamine from the samples with dopamine 
9.09 wt% and 19.2 wt% can be related to their larger aver-
age pore sizes compared with those for the materials with 
higher dopamine concentrations. The very slow release of 
dopamine after the initial hours may be related to a relatively 
strong interaction between the drug and the mesoporous 
silica through a hydrogen bond due to the affinity between 
the functional amine and hydroxyl groups of dopamine and 
the silanol groups present on the sol–gel silica, as indicated 
by the relatively polar hydrophilic character of the drug. 
These results are in agreement with those obtained from the 
theoretic calculations, although the release rate cannot be 
adequately predicted. The strength of interaction between 
dopamine and the silica network is expected to depend on 
the pH of the solution, indicating that the in vivo release rate 
will be conditioned by the properties of the local environ-
ment around the reservoir.
In vivo dopamine studies
Rats with lesions induced by 6-hydroxydopamine performed 
tight, full rotations toward the nonlesioned side (contralateral 
turns) after apomorphine challenge. Two weeks after the 
lesion, 17 animals met the criteria of performing a minimum 
of 100 contralateral turns in 90 minutes (511 ± 70, range 
104–1104).
No dyskinesias or unexpected motor abnormalities 
were observed in animals implanted with silica or silica–
dopamine. Comparisons of circling behavior recorded after 
the first and second apomorphine challenges showed different 
time-course profiles in the animals without striatal implants   
(Figure 16A), in those implanted with an empty silica res-
ervoir (Figure 16C), as well as in those bearing the silica–
dopamine complex (Figure 16E).
In the nonimplanted group, the onset of rotations was 
faster and their duration was longer at 24 weeks than at two 
weeks after lesion surgery (Figure 16A). The cumulative 
number of contralateral turns two weeks after the lesion was 
341 ± 91, and was significantly increased to 572 ± 26 at 24 
weeks after the lesion (Figure 16B).
In animals with the empty silica reservoir, there were 
no differences in the onset, intensity, or duration of circling 
recorded 24 weeks after the lesion (16 weeks after implan-
tation) in comparison with those recorded two weeks after 
the lesion (six weeks before implantation, Figure 16C). The 
cumulative number of contralateral turns recorded before 
implantation was 452 ± 60, and this number did not change 
significantly after implantation (480 ± 92, Figure 16D).
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Figure 16 Temporal profile and total number of turns induced by apomorphine in 
hemiparkinsonian rats. A, C, and E illustrate the time course of contralateral circling 
after apomorphine challenge (t = 0). B, D, and F show the cumulative number of 
turns during 90 minutes. A) Animals without an implant (n = 4) performed more 
turns during the evaluation at week 24 than at week 2 after lesion. Two-way analysis 
of variance revealed a significant effect of week (F1,540 = 91.4, P , 0.0001) and time 
(F89,540 = 5.1; P , 0.0001), but not of the interaction between the two factors 
(F89,540 = 0.9; P . 0.05). B) cumulative turns of animals without implant (paired 
t-test, t[3] = 3.1, *P = 0.027). C) Animals implanted with an empty silica–dopamine 
reservoir (n = 8) showed no difference in circling behavior between weeks 2 and 
24  after  lesion.  Two-way  analysis  of  variance  showed  no  significant  effects  of 
week (F1.1260 = 3.3, P . 0.05), time (F89,1260 = 5.0, P . 0.05), or interaction 
between the two factors (F89,1260 = 1.0, P . 0.05). D) cumulative turns of animals 
with  silica–dopamine  implants  (paired  t-test,  t[7]  =  0.3,  P  .  0.05).  E)  Animals 
implanted with silica–dopamine (n = 5) performed fewer turns during week 24 than 
during week 2 after lesion. Two-way analysis of variance revealed a significant effect 
of week (F1,720 = 280; P , 0.0001), but not of time (F89,720 = 0.599; P . 0.05) or 
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In animals implanted with silica–dopamine, a significant 
reduction of circling was observed 24 weeks after the 
lesion (16 weeks after implantation) in comparison with 
those recorded two weeks after the lesion (six weeks 
before implantation, Figure 16E). The cumulative number 
of contralateral turns recorded before implantation was 
744 ± 174, and was significantly reduced to 289 ± 127 at 
24 weeks after the lesion (Figure 16F).
When the rotations recorded on the second test were 
expressed as a percentage of the circling values measured 
on the first test, it was found that the silica–dopamine 
group, but not the silica group, had a significant reduction 
of circling behavior, in comparison with the nonimplanted 
group (Figure 17).
Consistent with previous studies,27,36 here we found that 
unilateral dopamine denervation with 6-hydroxydopamine, a 
catecholamine selective neurotoxin, caused motor asymmetry 
in rats, which displayed rotational behavior contralateral 
to the lesioned side after a challenge with apomorphine, a 
dopamine agonist. Earlier studies have shown that this effect 
occurs only in rats bearing a loss of dopaminergic neurons 
in the substantia nigra pars compacta of at least 90%.37 
Using the tyrosine hydroxylase immunostaining protocol 
we have previously confirmed that the method of surgical 
lesion used in the present study produces more than 90% of 
dopamine denervation in the substantia nigra pars compacta 
and ipsilateral striatum.38
It is important to note that the inhibitory effect of silica–
dopamine implants on apomorphine-induced circling was 
observed 16 weeks after surgery, suggesting that they were 
still releasing dopamine in the surrounding striatal tissue. 
Although the residual content of dopamine in the implants 
was not determined, its possible presence in the reservoirs was 
suggested by the results of the histologic analysis carried out 
24–32 weeks after implantation. Because paraformaldehyde 
is a strong oxidizing agent, it was expected that dopamine 
remaining in the cylinder would be oxidized during the 
fixation procedure. In fact, a reddish-brown color was always 
observed in the trajectory of nanostructured silica–dopamine 
implants, but not in those of empty silica reservoirs, which 
appeared translucent. This may be interpreted as evidence that 
the nanostructured matrix material still contained dopamine 
after six or eight months. Indeed, in vitro studies have shown 
that dopamine molecules embedded in silica nanostructured 
material remain stable for a long time.26
Histologic analysis revealed that the silica nanostructured 
implants were always located in the lateral region of the 
striatum. In all cases, the implants containing dopamine 
showed a reddish-brown color, suggesting the presence 
of oxidized dopamine (Figures 18A and 18B), while 
implants without dopamine were always translucent   
(Figures 18C and 18D).
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Conclusion
We developed amorphous nanostructured silica–dopamine 
materials with morphology consisting of aggregated particles 
and sizes that depend on the quantity of dopamine contained 
in them. Dopamine was stabilized into this morphology, 
forming weak hydrogen bonds with Si-OH groups of silica. 
The in vitro dopamine release profiles indicate the existence 
of two different release steps, a fast-sustained release dur-
ing the first 24 hours and from then on a fixed slow rate of 
release.
The major finding of this study was that intrastriatal 
silica–dopamine implants in hemiparkinsonian rats reversed 
the rotational asymmetry induced by apomorphine, a dop-
amine agonist. In contrast, apomorphine-induced rotation 
increased in animals without an implant, and remained 
unchanged in animals implanted with an empty silica res-
ervoir. The striatal area in which the implants were situated 
has been reported by others as a region related to motor 
modulation.39 In rats implanted with the silica–dopamine 
nanomaterial, the number of apomorphine-induced rotations 
was reduced to 57% of preimplant values. This effect is 
similar to that observed after intrastriatal transplantation of 
dopaminergic embryonic cells, which reduce apomorphine-
induced circling behavior by about 50% of pregrafting values, 
an effect which was attributed to sprouting of dopaminergic 
axons.27
It should be noted that rats implanted with silica–
dopamine showed no signs of dyskinesias at any time, an 
observation which would be consistent with a slow and tonic 
dopamine release. This contrasts with the effect of intermit-
tent systemic L-dopa administration, which causes orofacial 
dyskinesias. In summary, because the nanostructured silica 
material has been found to be biocompatible with cerebral 
tissue,25 we may conclude that it has the potential to be used 
as a release system for dopamine in patients with Parkinson’s 
disease.
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